Price: $43.77
· 1 day: +2.77% · 5 days: -2.60% · 1 month: -11.14% · YTD: +18.27%
As of 2026-10-09 15:35 UTC.
52-week range: $25.78 – $53.92 (currently at 64% of the range).
The read
BAYN.DE is in a turning up, momentum soft. $45 is the level overhead; $43.17 the first support below.
4 of 6 technical checks lean bearish.
Price vs 50-day: below
Price vs 200-day: above
50d vs 200d avg: above
MACD: bearish
RSI momentum: 29
5-day tape: -2.6%
Trend
Turning up · below 50-day & 200-day
Momentum
RSI 29.13 · bearish · MACD bearish
Trend strength
ADX 27.7 · strong trend
Location
-9.2% vs 50-day MA
52-week range
-18% from high · +66% from low
Volatility
ATR 1.41 · ~3.2%/day
Key levels
Level
Type
Distance
$45.0 (resistance)
round
2.81%
$47.43 (resistance)
swing zone
8.36%
$48.2 (resistance)
sma 50
10.12%
$43.17 (support)
sma 200
-1.37%
$40.0 (support)
round
-8.61%
$39.56 (support)
swing zone
-9.62%
Indicators
RSI (14)
29.13
MACD
-1.3654
ADX (14)
27.7
ATR (14)
1.41
50-day average
$48.2
200-day average
$43.17
Next earnings: 2026-11-03.
Latest BAYN.DE news
Bayer's CEO flattened the company. Now comes the hard part | Fortune — Bayer CEO Bill Anderson has restructured the company over three years following significant financial challenges, with the organization now announcing a $2.2 billion investment in Ohio manufacturing and implementing majo (Fortune, 2026-10-07)
Trump Pitches Company Investment to Ohio Voters at Midterm Rally — President Donald Trump used a rally in Ohio to highlight major corporate investment plans in the state, aiming to bolster Republican candidates ahead of the November midterm elections. His speech near Dayton combined war (Bloomberg Business, 2026-10-04)
German Private Investment Key to Broad Recovery, Klingbeil Says — German Finance Minister Lars Klingbeil stated that the country must increase private investment alongside existing fiscal stimulus to support a broader recovery in Europe's largest economy. He acknowledged that governmen (Bloomberg Business, 2026-09-30)
Bayer faces trial test of remaining Roundup claims after US Supreme Court win — Bayer faces a new Missouri trial over three Roundup cancer claims, testing legal theories not addressed by a US Supreme Court ruling in its favor earlier this year. The company still faces approximately 65,000 claims in (Reuters, 2026-09-29)
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit — A federal judge in Delaware has denied requests from Pfizer, BioNTech, and Moderna to dismiss patent infringement lawsuits filed by Bayer's Monsanto unit over mRNA technology used in their COVID-19 vaccines. The cases, B (Reuters, 2026-09-28)